Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium.


Autoria(s): Milano G.; Bianciardi P.; Rochemont V.; Vassalli G.; Segesser L.K.; Corno A.F.; Guazzi M.; Samaja M.
Data(s)

2011

Resumo

Although chronic hypoxia is a claimed myocardial risk factor reducing tolerance to ischemia/reperfusion (I/R), intermittent reoxygenation has beneficial effects and enhances heart tolerance to I/R. AIM OF THE STUDY: To test the hypothesis that, by mimicking intermittent reoxygenation, selective inhibition of phosphodiesterase-5 activity improves ischemia tolerance during hypoxia. Adult male Sprague-Dawley rats were exposed to hypoxia for 15 days (10% O₂) and treated with placebo, sildenafil (1.4 mg/kg/day, i. p.), intermittent reoxygenation (1 h/day exposure to room air) or both. Controls were normoxic hearts. To assess tolerance to I/R all hearts were subjected to 30-min regional ischemia by left anterior descending coronary artery ligation followed by 3 h-reperfusion. Whereas hypoxia depressed tolerance to I/R, both sildenafil and intermittent reoxygenation reduced the infarct size without exhibiting cumulative effects. The changes in myocardial cGMP, apoptosis (DNA fragmentation), caspase-3 activity (alternative marker for cardiomyocyte apoptosis), eNOS phosphorylation and Akt activity paralleled the changes in cardioprotection. However, the level of plasma nitrates and nitrites was higher in the sildenafil+intermittent reoxygenation than sildenafil and intermittent reoxygenation groups, whereas total eNOS and Akt proteins were unchanged throughout. CONCLUSIONS: Sildenafil administration has the potential to mimic the cardioprotective effects led by intermittent reoxygenation, thereby opening the possibility to treat patients unable to be reoxygenated through a pharmacological modulation of NO-dependent mechanisms.

Identificador

https://serval.unil.ch/?id=serval:BIB_071AE3CEB695

isbn:1932-6203 (Electronic)

pmid:22140481

doi:10.1371/journal.pone.0027910

isiid:000298163400021

http://my.unil.ch/serval/document/BIB_071AE3CEB695.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_071AE3CEB6953

Idioma(s)

en

Direitos

info:eu-repo/semantics/openAccess

Fonte

Plos One, vol. 6, no. 11, pp. e27910

Palavras-Chave #Animals; Apoptosis/drug effects; Body Weight/drug effects; Cardiomegaly/blood; Cardiomegaly/complications; Cardiotonic Agents/pharmacology; Cell Hypoxia/drug effects; Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism; Male; Myocardial Infarction/blood; Myocardial Infarction/complications; Myocardium/enzymology; Myocardium/pathology; Nitric Oxide/blood; Nitric Oxide Synthase Type III/metabolism; Oxygen/metabolism; Phosphodiesterase 5 Inhibitors/pharmacology; Polycythemia/blood; Polycythemia/complications; Proto-Oncogene Proteins c-akt/metabolism; Rats; Rats, Sprague-Dawley; Signal Transduction/drug effects
Tipo

info:eu-repo/semantics/article

article